These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 35138911)
41. Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia. Kirkey DC; Loeb AM; Castro S; McKay CN; Perkins L; Pardo L; Leonti AR; Tang TT; Loken MR; Brodersen LE; Loeb KR; Scheinberg DA; Le Q; Meshinchi S Blood Adv; 2023 Apr; 7(7):1178-1189. PubMed ID: 35984639 [TBL] [Abstract][Full Text] [Related]
42. PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer. van Amerongen RA; Tuit S; Wouters AK; van de Meent M; Siekman SL; Meeuwsen MH; Wachsmann TLA; Remst DFG; Hagedoorn RS; van der Steen DM; de Ru AH; Verdegaal EME; van Veelen PA; Falkenburg JHF; Heemskerk MHM Front Immunol; 2023; 14():1121973. PubMed ID: 37026005 [TBL] [Abstract][Full Text] [Related]
43. Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells. Klar R; Schober S; Rami M; Mall S; Merl J; Hauck SM; Ueffing M; Admon A; Slotta-Huspenina J; Schwaiger M; Stevanović S; Oostendorp RA; Busch DH; Peschel C; Krackhardt AM Leukemia; 2014 Dec; 28(12):2355-66. PubMed ID: 24736212 [TBL] [Abstract][Full Text] [Related]
44. Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination. Busse A; Letsch A; Scheibenbogen C; Nonnenmacher A; Ochsenreither S; Thiel E; Keilholz U J Transl Med; 2010 Jan; 8():5. PubMed ID: 20092642 [TBL] [Abstract][Full Text] [Related]
46. Development of genetically engineered CD4+ and CD8+ T cells expressing TCRs specific for a M. tuberculosis 38-kDa antigen. Luo W; Zhang XB; Huang YT; Hao PP; Jiang ZM; Wen Q; Zhou MQ; Jin Q; Ma L J Mol Med (Berl); 2011 Sep; 89(9):903-13. PubMed ID: 21556811 [TBL] [Abstract][Full Text] [Related]
47. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. Koesters R; Linnebacher M; Coy JF; Germann A; Schwitalle Y; Findeisen P; von Knebel Doeberitz M Int J Cancer; 2004 Apr; 109(3):385-92. PubMed ID: 14961577 [TBL] [Abstract][Full Text] [Related]
48. Signatures of recent activation identify a circulating T cell compartment containing tumor-specific antigen receptors with high avidity. Purcarea A; Jarosch S; Barton J; Grassmann S; Pachmayr L; D'Ippolito E; Hammel M; Hochholzer A; Wagner KI; van den Berg JH; Buchholz VR; Haanen JBAG; Busch DH; Schober K Sci Immunol; 2022 Aug; 7(74):eabm2077. PubMed ID: 35960818 [TBL] [Abstract][Full Text] [Related]
49. Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies. Jahn L; van der Steen DM; Hagedoorn RS; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH Oncotarget; 2016 Nov; 7(47):77021-77037. PubMed ID: 27776339 [TBL] [Abstract][Full Text] [Related]
50. Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma. Tan Q; Zhang C; Yang W; Liu Y; Heyilimu P; Feng D; Xing L; Ke Y; Lu Z J Immunother Cancer; 2019 Aug; 7(1):232. PubMed ID: 31462302 [TBL] [Abstract][Full Text] [Related]
51. [Cytotoxicity of T cells transduced with WT1 peptide-specific T-cell receptor gene against human lung cancer cells in vitro]. An J; Cai SW; Li Y; Zhang J Nan Fang Yi Ke Da Xue Xue Bao; 2014 Aug; 34(9):1319-23. PubMed ID: 25263367 [TBL] [Abstract][Full Text] [Related]
52. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study. Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696 [TBL] [Abstract][Full Text] [Related]